Registry to Collect Information on Pregnancy, Neonatal, and Infant Outcomes in Pregnant Women Exposed to QUVIVIQ®

A) Eligibility criteria for prospective pregnancies:

Inclusion Criteria:

1. Diagnosis of insomnia disorder prior to pregnancy.

2. Pregnancy is ongoing and outcome of pregnancy (i.e., pregnancy loss or live birth)is not known.

3. One of the following:

4. Exposure to QUVIVIQ at any time during the current pregnancy or within 5half-lives prior to conception.

5. Exposure to other, non-orexin receptor antagonist medications for insomniaduring pregnancy or within 5 half-lives of the respective insomnia medicationprior to conception.

6. No exposure to any insomnia medication during pregnancy and within 5 half-livesof any insomnia medication taken prior to conception.

Exclusion Criteria:

• Exposure to any orexin receptor antagonist other than QUVIVIQ - including BELSOMRA® (suvorexant), DAYVIGO® (lemborexant), any orexin receptor antagonist newly approvedduring the study period, or any orexin receptor antagonist in pre-market clinicalstudies - during the current pregnancy or within 5 half-lives of the respectivemedication prior to conception.

B) Eligibility criteria for retrospective pregnancies:

Inclusion criteria:

1. Diagnosis of insomnia disorder prior to pregnancy.

2. Pregnancy has ended.

3. Exposure to QUVIVIQ during pregnancy or within 5 half-lives prior to conception.

Exclusion criteria:

• Exposure to any orexin receptor antagonist other than QUVIVIQ - includingsuvorexant, lemborexant, any orexin receptor antagonist newly approved during thestudy period, or any orexin receptor antagonist in pre-market clinical studies -during pregnancy or within 5 half-lives of the respective medication prior toconception.